Monocyte enrichment from leukapheresis products by using the Elutra cell separator

BACKGROUND: Dendritic cells (DCs), used in clinical trials for cancer immunotherapy, require processing on an expanded scale to conform to current good manufacturing practice guidelines. This study evaluated a large‐scale monocyte enrichment procedure with a commercially available cell separator (Elutra, Gambro BCT) and analyzed the capacity of enriched monocytes to differentiate into DCs.

[1]  B. Schuler-Thurner,et al.  Comparison of two apheresis systems for the collection of CD14+ cells intended to be used in dendritic cell culture , 2003, Transfusion.

[2]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[3]  P. Kokhaei,et al.  Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell–tumour hybrids in B-CLL , 2003, Leukemia.

[4]  E. Kaempgen,et al.  Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. , 2005, Journal of immunological methods.

[5]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Banchereau,et al.  CD40 Ligation on Human Cord Blood CD34+Hematopoietic Progenitors Induces Their Proliferation and Differentiation into Functional Dendritic Cells , 1997, The Journal of experimental medicine.

[7]  G. Schuler,et al.  Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. , 1999, Journal of immunological methods.

[8]  A. Enk,et al.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.

[9]  J. Weber,et al.  Phase I Trial Of Intravenous Peptide-Pulsed Dendritic Cells in Patients With Metastatic Melanoma , 2001, Journal of immunotherapy.

[10]  E. Gilboa.  The makings of a tumor rejection antigen. , 1999, Immunity.

[11]  R. Steinman,et al.  Active immunization against cancer with dendritic cells: The near future , 2001, International journal of cancer.

[12]  M. Loudovaris,et al.  Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. , 2001, Cytotherapy.

[13]  S. Vuk-Pavlović,et al.  Mature myeloid dendritic cells for clinical use prepared from CD14+ cells isolated by immunomagnetic adsorption. , 2001, Journal of hematotherapy & stem cell research.

[14]  L. Kanz,et al.  Approaches to Dendritic Cell‐Based Immunotherapy after Peripheral Blood Stem Cell Transplantation , 1999, Annals of the New York Academy of Sciences.

[15]  Gerold Schuler,et al.  Dendritic Cells as Vectors for Therapy , 2001, Cell.

[16]  R. van Furth,et al.  Anti-CD14 Monoclonal Antibodies Inhibit the Production of Tumor Necrosis Factor Alpha and Interleukin-10 by Human Monocytes Stimulated with Killed and Live Haemophilus influenzae or Streptococcus pneumoniaeOrganisms , 1999, Infection and Immunity.

[17]  D. Schadendorf,et al.  Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients , 2002, Transfusion.

[18]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[19]  R. Zimmermann,et al.  Collection of mononuclear cells in the Spectra for the generation of dendritic cells , 1999, Transfusion.

[20]  S. Rosenberg,et al.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.

[21]  Sun-Min Lee,et al.  Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. , 2002, Journal of immunological methods.

[22]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[23]  G. Ehninger,et al.  Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. , 2003, Journal of hematotherapy & stem cell research.

[24]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.